HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hagop Kantarjian Selected Research

bcr-abl Fusion Proteins

1/2022SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
1/2016Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
4/2012Treatment options for chronic myeloid leukemia.
8/2010Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
6/2010Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
5/2009First-line therapy for chronic myeloid leukemia: Past, present, and future.
1/2009Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
1/2009Treatment selection after imatinib resistance in chronic myeloid leukemia.
7/2008Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
3/2008BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hagop Kantarjian Research Topics

Disease

211BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/2022 - 01/2000
186Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 01/2002
125Neoplasms (Cancer)
10/2022 - 01/2002
120Leukemia
09/2022 - 03/2002
113Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2022 - 01/2002
112Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2022 - 03/2002
72Philadelphia Chromosome
01/2022 - 02/2002
40B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2022 - 03/2002
37Primary Myelofibrosis (Myelosclerosis)
12/2021 - 09/2002
34Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 01/2002
27Acute Promyelocytic Leukemia
01/2020 - 05/2003
24Thrombocytopenia (Thrombopenia)
01/2022 - 04/2004
23Blast Crisis (Blast Phase)
01/2021 - 10/2002
23Residual Neoplasm
01/2021 - 11/2006
20Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
01/2021 - 06/2002
18Anemia
01/2022 - 03/2002
18Myeloid Leukemia (Leukemia, Myelocytic)
01/2021 - 04/2006
17Disease Progression
12/2021 - 05/2002
15Infections
01/2022 - 03/2003
15Lymphoma (Lymphomas)
01/2022 - 06/2005
14Chromosome Aberrations (Chromosome Abnormalities)
01/2022 - 05/2002
11Splenomegaly
01/2018 - 03/2002
11Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2008 - 09/2002
10Pneumonia (Pneumonitis)
01/2022 - 01/2003
10Multiple Myeloma
10/2017 - 03/2003
10Polycythemia Vera
04/2017 - 06/2003
9Exanthema (Rash)
01/2021 - 06/2009
9Pathologic Complete Response
07/2020 - 01/2003
9Neutropenia
02/2019 - 09/2003
9Nausea
09/2018 - 10/2002
9Hypereosinophilic Syndrome (Loeffler Endocarditis)
06/2013 - 09/2002
8Hemorrhage
11/2019 - 06/2009
8Fever (Fevers)
10/2018 - 01/2003
7Diarrhea
01/2017 - 12/2003
7Systemic Mastocytosis
09/2013 - 05/2004
7Essential Thrombocythemia
08/2013 - 01/2003
6Hypertension (High Blood Pressure)
12/2020 - 01/2011
6Burkitt Lymphoma (Burkitt's Lymphoma)
12/2020 - 03/2002
6Sepsis (Septicemia)
07/2020 - 08/2004
6Cytopenia
01/2020 - 06/2007

Drug/Important Bio-Agent (IBA)

148Imatinib Mesylate (Gleevec)FDA Link
01/2020 - 01/2000
85Tyrosine Kinase InhibitorsIBA
01/2022 - 11/2006
56Cytarabine (Cytosar-U)FDA LinkGeneric
05/2022 - 03/2002
37Dasatinib (BMS 354825)FDA Link
11/2020 - 06/2006
36DecitabineFDA Link
12/2021 - 03/2003
32Proteins (Proteins, Gene)FDA Link
01/2019 - 03/2002
30Pharmaceutical PreparationsIBA
10/2021 - 04/2004
28Phosphotransferases (Kinase)IBA
06/2018 - 12/2003
23Rituximab (Mabthera)FDA Link
12/2021 - 11/2003
23fludarabineIBA
12/2021 - 03/2003
23nilotinibFDA Link
03/2016 - 07/2005
22bcr-abl Fusion ProteinsIBA
01/2022 - 01/2000
21Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2021 - 03/2002
21Monoclonal AntibodiesIBA
01/2021 - 09/2004
20Azacitidine (5 Azacytidine)FDA Link
01/2019 - 01/2005
19Arsenic Trioxide (Trisenox)FDA Link
01/2021 - 05/2003
19Clofarabine (Clolar)FDA Link
01/2021 - 10/2003
18ponatinibIBA
09/2022 - 11/2012
18Inotuzumab OzogamicinIBA
01/2022 - 06/2013
18Vincristine (Oncovin)FDA LinkGeneric
10/2021 - 03/2002
16Tretinoin (Retinoic Acid)FDA LinkGeneric
11/2019 - 05/2003
15InterferonsIBA
01/2021 - 03/2003
15Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
01/2018 - 01/2003
14Gemtuzumab (Mylotarg)FDA Link
01/2020 - 01/2002
13ruxolitinibIBA
01/2021 - 04/2010
13Interferon-alpha (Interferon Alfa)IBA
06/2012 - 01/2000
12venetoclaxIBA
05/2022 - 03/2014
12blinatumomabIBA
01/2022 - 01/2017
12ibrutinibIBA
12/2021 - 06/2014
12Dexamethasone (Maxidex)FDA LinkGeneric
10/2021 - 03/2002
12Doxorubicin (Adriamycin)FDA LinkGeneric
10/2021 - 03/2002
11Biomarkers (Surrogate Marker)IBA
01/2021 - 06/2002
11Core Binding Factors (Core-Binding Factor)IBA
01/2021 - 12/2008
11DNA (Deoxyribonucleic Acid)IBA
10/2020 - 12/2003
11Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
05/2015 - 03/2003
10Lenalidomide (CC 5013)FDA Link
10/2022 - 05/2007
10Hemoglobins (Hemoglobin)IBA
07/2018 - 06/2004
9Agammaglobulinaemia Tyrosine KinaseIBA
01/2022 - 06/2014
9CytokinesIBA
12/2021 - 09/2002
9Sorafenib (BAY 43-9006)FDA Link
11/2020 - 12/2008
9fms-Like Tyrosine Kinase 3IBA
01/2020 - 05/2004
8L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2022 - 03/2002
8Alemtuzumab (Campath)FDA Link
06/2013 - 11/2005
7Biological ProductsIBA
01/2021 - 05/2004
7HomoharringtonineIBA
01/2019 - 01/2007
7Prednisone (Sone)FDA LinkGeneric
12/2018 - 09/2010
7Methotrexate (Mexate)FDA LinkGeneric
01/2016 - 03/2002
7Alkylating AgentsIBA
06/2012 - 05/2004
7tipifarnib (R115777)IBA
03/2011 - 10/2002
6CreatinineIBA
01/2022 - 10/2008

Therapy/Procedure

287Therapeutics
10/2022 - 03/2002
98Drug Therapy (Chemotherapy)
07/2022 - 03/2002
23Stem Cell Transplantation
01/2022 - 07/2003
20Salvage Therapy
01/2022 - 04/2003
14Hematopoietic Stem Cell Transplantation
01/2020 - 02/2007
14Induction Chemotherapy
01/2017 - 01/2003
8Transplantation
01/2022 - 09/2003
7Drug Tapering
11/2020 - 12/2003
6Radiotherapy
10/2022 - 09/2004
6Cell Transplantation
01/2022 - 01/2007